Multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over the course of approximately 9 weeks. Qualified subjects are randomized 1:1:1 to receive either High Dose SkQ1 ophthalmic solution, Low Dose SkQ1 ophthalmic solution, or Placebo (vehicle of SkQ1 ophthalmic solution).
The Primary Endpoints are:
Change from Baseline (Visit 2) to Visit 5 in Corneal Fluorescein Staining;
Change from Baseline (Visit 2) to Visit 5 in Grittiness Symptom
